Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting
  • Home
  • Search results for: 'gambogic acid 20293'

Search results for: 'gambogic acid 20293'

Items 41-49 of 49

Page
per page
  1. BLZ945
    B4899 BLZ945
     1 Citation
    Target: CSF-1R
    Summary: CSF-1R kinase inhibitor
      insoluble in EtOH; insoluble in H2O; ≥19.9 mg/mL
  2. Peptide YY(3-36), PYY, human
    A1115 Peptide YY(3-36), PYY, human
    Target: NPY Receptors
    Summary: Y2R agonist
      ≥405 mg/mL
  3. Panobinostat (LBH589)
    A8178 Panobinostat (LBH589)
     10 Citation
    Target: Histone Deacetylases (HDACs)
    Summary: HDAC inhibitor
      insoluble in H2O; insoluble in EtOH; ≥17.47 mg/mL
  4. EPZ5676
    A4166 EPZ5676
     1 Citation
    Target: DOT1L
    Summary: DOT1L inhibitor,potent and SAM competitive
      ≥28.15 mg/mL
  5. Bardoxolone methyl
    A3221 Bardoxolone methyl
    Target: Nrf2
    Summary: IKK inhibitor, potent antioxidant inflammation modulator
      ≥25.3 mg/mL
  6. VX-222 (VCH-222, Lomibuvir)
    A4032 VX-222 (VCH-222, Lomibuvir)
    Target: HCV polymerase
    Summary: NNI of HCV RNA polymerase
      ≥44.6 mg/mL
  7. PF-562271
    A8310 PF-562271
     1 Citation
    Target: FAK|Pyk2
    Summary: ATP-competitive FAK inhibitor, reversible
      ≥25.35 mg/mL
  8. PF-00562271
    A8320 PF-00562271
    Target: FAK|Pyk2
    Summary: FAK/Pyk2 inhibitor,potent and ATP-competitive
      insoluble in EtOH; insoluble in H2O; ≥11.1 mg/mL
  9. PF-562271 HCl
    A8345 PF-562271 HCl
    Target: FAK|Pyk2
    Summary: FAK/Pyk2 inhibitor
      ≥26.35 mg/mL

Items 41-49 of 49

Page
per page
Shop By
Now Shopping by
  1. Specificity Selective Remove This Item
Clear All
Shopping Options
Category
  1. Signaling Pathways 39item
  2. Natural Products 4item
  3. Peptides 4item
Reversibility
  1. Reversible 5item
  2. Irreversible 1 item
Target
  1. Proteasome 1 item
  2. Histone Deacetylases (HDACs) 4item
  3. Aurora Kinases 1 item
  4. CSF-1R 1 item
  5. Farnesoid X receptors (FXRs) 1 item
  6. LPA Receptors 2item
  7. DOT1L 1 item
  8. Nrf2 1 item
  9. Glucagon-like peptide 1 (GLP-1) receptors 1 item
  10. Neuraminidases (NA) 1 item
  11. RARs 4item
  12. FAK 3item
  13. CREBBP 1 item
  14. EP300 1 item
  15. Pyk2 3item
  16. Calcium ionophores 1 item
  17. Insulin and Insulin-like Receptors 1 item
  18. AdipoR2 1 item
  19. Fatty-acid-binding proteins (FABPs) 1 item
  20. Free Fatty Acid Receptors 2item
  21. Farnesyl Diphosphate Synthases 1 item
  22. Calcium-activated chloride channels (CaCC) 1 item
  23. GPR35 1 item
  24. NPY Receptors 1 item
  25. RAR/RXR 1 item
  26. Opioid receptors 1 item
  27. Histamine H2 Receptors 1 item
  28. TRP Channel 1 item
  29. Xanthine oxidoreductases 1 item
  30. fibrinolysis 1 item
  31. Antioxidants 1 item
  32. GPR40 1 item
  33. PPAR 1 item
  34. HCV polymerase 1 item
  35. FAAH 1 item
Reported Experiments
  1. Animal Experiments 44item
  2. Cell Experiments 30item
Related Disease
  1. Acute Myelogenous Leukemia 1 item
  2. Acute Myeloid Leukemia 1 item
  3. Bladder Cancer 1 item
  4. Brain Injuries Studies 1 item
  5. Breast Cancer 7item
  6. Cancer 22item
  7. Colon Cancer 2item
  8. Colorectal Cancer 3item
  9. Epilepsy 1 item
  10. Glioblastoma 1 item
  11. Glioma 2item
  12. Hepatitis C 1 item
  13. Hepatocellular Carcinoma 3item
  14. HIV Infections 2item
  15. Inflammation 1 item
  16. Inflammatory Diseases 1 item
  17. Influenza 1 item
  18. Lymphoma 1 item
  19. Melanoma 1 item
  20. Mixed Lineage Leukemia 1 item
  21. Multiple Myeloma 1 item
  22. Myeloma 1 item
  23. Non-small Cell Lung Cancer 1 item
  24. Ovarian Cancer 1 item
  25. Pain Relief 1 item
  26. Pancreatic Cancer 7item
  27. Prostate Cancer 4item
  28. Renal Cancer 1 item
  29. Renal Cell Carcinoma 2item
  30. Type 2 Diabetes 5item